Clinical Pharmacology of Mycophenolic Acid as Immunosuppressant in Organ Transplaantation |
Kang, Ju-Seop
(Department of Pharmacology & Clinical Pharmacology Laboratory, College of Medicine, Hanyang University)
Lee, Joo-Won (Department of Pharmacology & Clinical Pharmacology Laboratory, College of Medicine, Hanyang University) Jhee, Ok-Hwa (Department of Pharmacology & Clinical Pharmacology Laboratory, College of Medicine, Hanyang University) Om, Ae-Son (Department of Food & Nutrition, College of Human Ecology & Institute of Biomedical Science, Hanyang University) Lee, Min-Ho (Department of Internal Medicine, College of Medicine, Hanyang University) Shaw, Leslie M. (Department of Pathology & Lab Medicine, Medical School, University of Pennsylvania) |
1 | Yeung, S., Tong, K. L., Tsang, W. K., Chan, H. W. and Chan, A. Y. (2000) Pharmacokinetic study of mycophenolate mofetil in asian renal transplant recipients. Transplant. Proc. 32, 1753-1754 DOI ScienceOn |
2 | Yeung, S., Tong, K. L., Tsang, W. K., Tang, H. L., Fung, K. S., Chan, H. W., Chan, A. Y. and Chan, L. (2001). Determination of mycophenolate mofetil area under the curve by limited sampling strategy. Transplant. Proc. 33, 1052-1053 |
3 | Smak, P. J., Hesse, C. J., van Gelder, T., van der Mast, B. J., IJzermans, J. N., van Besouw, N. M. and Weimar, W. (1998). Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients. Transplant. Proc. 30, 1192-1193 DOI ScienceOn |
4 | Sollinger, H. W. (1995). Mycophenolate mofetil for the prevention of acute rejection in primary cadavaric renal allograft recipients. Transplantation 60, 225-232 DOI |
5 | Sollinger, H. W, Deierhoi, M. H., Belzer, F. O., Diethelm, A. G. and Kauffman, R. S. (1992). RS-61443-a phase I clinical trial and pilot rescue study. Transplantation 53, 428-432 DOI ScienceOn |
6 | Taylor, D.O., Ensley, R. D., Olsen, S. L., Dunn, D. and Renlund, D. G. (1994) Mycophenolate mofetil(RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant. 13, 571-582 |
7 | Goldblum, R (1993). Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin. Exp. Rheumatol. 11, S117-119 |
8 | Kobashigawa, J., Miller, L., Renlund, D., Mentzer, R., Alderman, E., Bourge, R., Costanzo, M., Eisen, H., Dureau, G., Ratkovec, R., Hummel, M., Ipe, D., Johnson, J., Keogh, A., Mamelok, R., Mancini, D., Smart, F. and Valantine, H. (1998). A randomized, active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66, 507-515 DOI ScienceOn |
9 | Shaw, L. M., Korecka, M., Aradhye, S., Grossman, R., Barker, C, Naji, A. and Brayman, K. L. (1998). Scientific principles for mycophenolic acid therapeutic drug monitoring. Transplant. Proc. 30, 2234-2236 DOI ScienceOn |
10 | Shipkova, M., Armstrong, V. W., Schneider, T, Niedmann, P. D., Schutz, E., Wieland, E. and Oellerich, M. (1999). Stability of mycophenolic acid and mycophenolic acid glucuronide in human plasma. Clin. Chem. 45, 127-129 |
11 | Vanrenterghem, Y (1997). The use of mycophenolate mofetil(Cellcept) in renal transplantation. Nephron 76, 392-399 DOI ScienceOn |
12 | Vasquez, E. M., Sifontis, N. M., Pollak, R. and Benedetti, E. (2001). Impact of mycophenolate mofetil on recurrent rejection in kindney transplants patients. Clin. Transplant. 15, 253-257 DOI ScienceOn |
13 | Weber, L. T., Lamersdorf, T., Shipkova, M., Niedmann, P. D., Wiesel, M., Zimmerhackl, L.B., Staskewitz, A., Schutz, E., Mehls, O., Oellerich, M., Armstrong, V.W. and Tonshoff, B. (1999). Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: A longitudinal study in pediatric patients. Ther. Drug Manit. 21, 498-506 DOI ScienceOn |
14 | Weber, L. T., Shipkova, M., Lamersdorf, T., Niedmann, P. D., Wiesel, M., Mandelbaum, A., ZimmerhackL L. B .. Schutz. E., Mehls, O., Oellerich, M., Armstrong, V. W. and Tonshoff, B. (1998). Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adults renal transplant recipients. J Am. Soc. Nephrol. 9, 1511-1520 |
15 | Kaplan, B., Meier-Kriesche, H. U., Friedman, G, Mulgaonkar, S., Gruber, S., Korecka, M., Brayman, K.L. and Shaw, LM. (1999). The effect of renal insufficiency on mycophenolic acid protein binding. J. Clin. Pharmacol. 39, 715-720 DOI |
16 | Meiser, B. M., Pfeiffer, M., Schmidt, D., Ueberfuhr, P., Reichenspumer, H., Paulus, D., von Scheidt, W., Kreuzer, E., Seidel, D. and Reichart, B. (1999). The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough levels. Transplant. Proc. 31, 84-87 |
17 | Nowak, I. and Shaw, L. M. (1995). Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin. Chem. 41, 1011-1017 |
18 | Zimmer-Molsberger, B., Knauf: W. and Thiel E. (1997). Mycophenolate mofetil for severe autoimmune hematolytic anemia. Lancet 350, 1003-1004 DOI ScienceOn |
19 | Perez, R.V., Johnson J, Hubbard, N. E., Erickson, K., Morgan, M, Kim, S., Rudich, SM, Katmelson, S, German, J. B. (1998). Selective targeting of Kupffer cells with liposomal butyrate arguments portal venous transfusion-induced immuno-suppression. Transplantation. 65, 1294-1298 DOI ScienceOn |
20 | Zhu, B. T., Suchar, L. A., Huang, M. T. and Conney, A. H. (1996). Similarities and differences in the glucuronidation of estradiol and estrone by UDP-glucuronosyltransferase in liver microsomes from male and female rats. Biochem. Pharmacol. 51, 1195-1202 DOI ScienceOn |
21 | Zucker, K., Rosen, A., Tsaroucha, A., de Faria, L., Roth, D., Ciancio, G., Esquenazi, V; Burke, G., Tzakis, A. and Miller, J. (1997). Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving prograft and CellCept in combination therapy. Transplant. Proc. 29, 334-336 DOI ScienceOn |
22 | Zucker, K., Tsaroucha, A., Olson, L., Esquenazi, V., Tzakis, A. and Miller, J. (1999). Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther. Drug Monit. 21, 35-43 DOI ScienceOn |
23 | Benfield, M. R., Symons, J. M., Bynon, S., Echkoff, D., Herrin, J., Harmon, W. E. and Kohaut, E. C. (1999) Mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant. 3, 33-37 DOI ScienceOn |
24 | Houde, I., Isenring, P., Boucher, D., Noel, Rand Lachanche, J. G. (2000). Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation. Transplantation 70, 1251-1253 DOI ScienceOn |
25 | Arai, M., Thurman, R. G. and Lemasters, J. J. (1999). Involvement of Kupffer cells and sinusoidal endothelial cells in ischemic preconditioning to rat livers stored for transplantation. Transplant. Proc. 31, 425-427 DOI ScienceOn |
26 | Ensley, R. D., Bristow, M. R., Olsen, S. L., Taylor, D. O., Hammond, E. H., O'Connell, J. B., Dunn, D., Osburn, L., Jones, K. W. and Kauffman, R.S. (1993). The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 56, 75-82 DOI ScienceOn |
27 | Hale, M. D., Nicholls, A. J., Bullingham, R. E., Hene, R., Hoitsma, A., Squiffiet, J.P., Weimar, W., Vanrenterghem, Y., Van de Woude, F. J. and Verpooten, G. A. (1998) The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin. Pharmacol. Ther. 64, 672-683 DOI ScienceOn |
28 | Shaw, L. M., Korecka, M., DeNofrio, D. and Brayman, K. L. (2001). Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin. Biochem. 34, 17-22 DOI ScienceOn |
29 | Takahashi, K., Ochiai, T, Uchida, K., Yasumura, T, Ishibashi, M., Suzuki, S., Otsubo, O., Isono, K., Takagi, H. and Oka, T. (1995). Pilot study of my cop he no late mofetil(RS-61443) in the prevention of acute rejection following renal transplanration in Japanese patients. Transplant. Proc. 27, 1421-1424 |
30 | van Gelder, T., Hilbrands, L. B., Vanrenterghem, Y, Weimar, W, De Fijter, J. W., Squiffiet, J. P., Hene, R. J., Verpooten, G. A., Navarro, M. T., Hale, M. D. and Nicholls, A. J. (1999). A randomized double-blinded, multicenter plasma concentra-tion controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of the acute rejection after kidney transplantation. Transplantation 68, 261-266 DOI ScienceOn |
31 | Yamani, M. H., Starling, R. C., Goormastic, M., Van Lente, E, Smendira, N., McCarthy, P. and Young, J. B. (2000). The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 69, 2326-2330 DOI ScienceOn |
32 | Bullingham, R., Shah, J., Goldblum, R. and Schiff, M. (1996). Effects of food and antacid on the pharmacokinetics of single dose of mycophenolate mofetil in rheumatoid arthritis patients. Br. J Clin. Pharmacol. 41, 513-516 DOI ScienceOn |
33 | Armstrong, V. W., Shipkova, M., Schutz, E., Weber, L., Tonshoff, B. and Oellerich, M. (2001) German study group on mmf therapy in pediatric renal transplant recipients. Monitoring of mycophenolic acid in pediatric renal transplant recipients. Transplant. Proc. 33, 1040-1043 DOI ScienceOn |
34 | Blaheta, R. A., Nelson, K., Oppermann, E., Leckel, K., Harder, S., Cinatl, J., Weber, S., Shipkova, M., Encke, A. and Markus, B. H. (2000) Mycophenolate mofetil decreases endothelial prostaglandin in response to allogeneic T cells or cytokines. Transplantation 69, 1977-1981 DOI ScienceOn |
35 | Brusa, P., Ceruti, M., Casullo, R., Dosio, F., Squiccimarro, G, Segoloni, G. P. and Cattel, L. (2000). Pharmacokinetic monitoring of mycophenolate mofetil in kidney transplanted patients. Farmaco. 55, 270-275 DOI ScienceOn |
36 | Bullingham, R. E., Nicholls, A. J. and Kamm, B. R. (1998). Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 34, 429-455 DOI ScienceOn |
37 | Bullingham, R. E., Nicholls, A. and Hale, M. (1996). Pharmacokinetics of mycophenolate mofetil(RS61443). A short review. Transplant. Proc. 28, 925-929 |
38 | Butani, L., Palmer, J., Baluarte, H. J. and Polinsky, M.S. (1999) Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. Transplantation 68, 83-86 DOI |
39 | Corna, D., Morigi, M., Facchinetti, D., Bertani, T., Zoja, C. and Remuzzi, G (1997). Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int. 51, 1583-1589 DOI ScienceOn |
40 | Demeure, C. E., Yang, L. P., Desjardins, C., Raynauld, P. and Delespesse, G. (1997). Prostaglandin primer-naive T cells for the production of anti-inflammatory cytokines. Eur. J. Imunol. 27, 3526-3531 DOI ScienceOn |
41 | Facts and Comparisons St. Louis. Drug Facts and Comparisons, 57th Edi, 2003, pp. 1752-26 |
42 | DeNofrio, D., Loh, E., Kao, A., Korecka, M., Pickering, F. W., Craig, K. A. and Shaw, L. M. (2000). Mycophenolic acid concentrations are associated with cardiac allograft rejection. J. Heart Lung Transplant. 19, 1071-1076 DOI ScienceOn |
43 | Ducloux, D., Fournier, V, Bresson-Vautrin, C., Rebibou. J. M., Billerey, C., Saint-Hillier, Y and Chalopin, J.M. (1998). Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated with nephrotoxicity: a preliminary report. Transplantation 65, 1504-1506 DOI ScienceOn |
44 | European Mycopheno1ate Mofeti1 Cooperative Study Group. (1995). Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 345, 1321-1325 DOI |
45 | Filler, G., Lepage, N., Delisle, B. and Mai, I. (2001). Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther. Drug Monit. 23, 514-519 DOI ScienceOn |
46 | Gavlik, A., Demirbas, A., Tsaroucha, A., Webb, M.G., Nery, J.R., Khan, M. F., Karatzas, T., Khan, R. T., Zucker, K., Viciana, A. L., Miller, J. A. and Tzakis, A.G. (1997). Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. Transplant. Proc. 29, 2971-2972 DOI ScienceOn |
47 | Gummert, J. F., Barten, M. J., Sherwood, S.W., van Gelder, T. and Morris, R.E. (1999). Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol. Exp. Ther. 291, 1100-1112 |
48 | Jain, A., Venkataramanan, R., Hamad, I.S., Zuckerman, S., Zhang, S., Lever, J., Warty, V.S. and Fung, J. J. (2001) Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplants treated with tacrolimus. J. Clin. Pharmacol. 41, 268-276 DOI ScienceOn |
49 | Halloran, P., Mathew, T., Tomlanovich, S., Groth, C., Hooftman, L. and Barker, C. (1997). Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 63, 39-47 DOI ScienceOn |
50 | Hollander, A. A., van Saase, J. L., Kootte, A. M., van Dorp, W.T., van Bockel, H. J., van Es, L. A. and van der Woude, F. J. (1995). Beneficial effects of conversion from cyclosporine to azathioprine after kidney transplantation. Lancet 345, 610-614 DOI ScienceOn |
51 | Johnson, H. J., Swan, S. K., Heim-Duthoy, K.L., Nicholls, A. J., Tsina, I. and Tarnowski, T. (1998). The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin. Pharmacol. Ther. 63, 512-518 DOI ScienceOn |
52 | Cattaneo, D., Gaspari, F., Ferrari, S., Stucchi, N., Del Priore, L., Perico, N., Gatti, E. and Remuzzi, G. (2001). Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin. Transplant. 15 402-409 DOI ScienceOn |
53 | Kaplan, B., Gruber, S. A., Nallamathou, R., Katz, S. M. and Shaw, L. M. (1998). Decreased protein binding of mycophenolic acid associated with leucopenia in a pancreas transplant recipient with renal failure. Transplantation 65, 1127-1129 DOI ScienceOn |
54 | Karim, M. Y., Alba, P., Cuadrado, M. J., Abbs, I. C., D'Cruz, D. P., Khamashta, M. A. and Hughes G. R. (2002). Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41, 876-882 DOI ScienceOn |
55 | Land, W., Schneeberger, H., Weiss, M., Ege, T. and Stumpfig, L. (2001). Mycophenolate mofetil monotherapy: An optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. Transplant. Proc. 33, 29S-35S |
56 | Keown, P., Landsberg, D., Halloran, P., Shoker, A., Rush, D., Jeffery, J., Russell, D., Stiller, C., Muirhead, N., Cole, E., Paul, L., Zaltzman, J., Loertscher, R., Daloze, P., Dandavino, R., Boucher, A., Handa, P., Lawen, J., Belitsky, P. and Parfrey, P. (1996). A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Transplantation 62, 1744-1752 DOI ScienceOn |
57 | Kirklin, J. K., Bourge, R. C., Naftel, D. C., Morrow, W. R., Deierhoi, M. H., Kauffman, R. S., White-Williams, C., Nomberg, R. I., Holman, W. L. and Smith, D. C. Jr. (1994). Treatment of recurrent heart rejection with mycophenolate mofetil(RS-61443): initial clinical experience. J. Heart Lung Transplant. 13, 444-450 |
58 | Klintmalm, G. B., Ascher, N. L., Busuttil, R. W., Deierhoi, M., Gonwa, T. A., Kauffman, R., McDiarmid, S., Poplawski, S., Sollinger, H. and Roberts, J. (1993). RS-61443 for treatmentresistant human liver rejection. Transplant. Proc. 25, 697 |
59 | Fulton, B. and Markham, A. (1996). Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51, 278-298 DOI ScienceOn |
60 | MacPhee, I. A., Bradley, J. A., Briggs, J. D., Junor, B. J., MacPherson, S. G., McMillan, M. A., Rodger, R. S. and Watson, M. A. (1998). Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation 66, 1186-1192 DOI ScienceOn |
61 | MacPhee, I. A., Spreafico, S., Bewick, M., Davis, C., Eastwood, J. B., Johnston, A., Lee, T. and Holt, D. W. (2000). Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int. 57, 1164-1168 DOI ScienceOn |
62 | Mourad, M., Malaise, J., Chaib Eddour, D., De Meyer, M., Konig, J., Schepers, R., Squiffiet, J.P. and Wallemacq, P. (2001). Pharmacokinetic basis for the efficient safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin. Chem. 47, 1241-1248 |
63 | Mathew, T. H. (1998). A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric transplantation; results at three years. Transplantation 65, 1450-1454 DOI ScienceOn |
64 | Meier-Kriesche, H. U., Ojo, A. O., Leichtman, A. B., Punch, J. D., Hanson, J. A., Cibrik, D. M. and Kaplan, B. (2000) Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am. Soc. Nephrol. 11, 2366-2370 |
65 | Morissette, P., Albert, C., Busque, S., St-Louis, G. and Vinet B. (2001). In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther. Drug Monit. 23, 520-525 DOI ScienceOn |
66 | Johnson, A. G, Rigby, R. J., Taylor, P. J., Jones, C. E., Allen, J., Franzen, K., Falk, M. C. and Nicol D. (1999). The kinetics of mycophenolic acid and its metabolite in adult kidney transplant recipients. Clin. Pharmacol. Ther. 66, 492-500 DOI ScienceOn |
67 | Neyts, J., Andrei, G. and De Clercq, E. (1998). The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of Acyclovir, Ganciclovir, and penciclovir in vitro and in vivo. Antimicrob. Agents Chemother. 42, 216-222 |
68 | Oellerich, M., Shipkova, M., Schutz, E., Wieland, E., Weber, L., Tonshoff, B. and Armstrong, V.W.: (2000). Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring. Ther. Drug Monit, 22, 20-26 DOI ScienceOn |
69 | Pescovitz, M. D., Conti, D., Dunn, J., Gonwa, T, Halloran, P., Sollinger, H., Tomlanovich, S., Weinstein, S., Inokuchi, S., Kiberd, B., Kittur, D., Merion, R.M., Norman, D., Shoker, A., Wilburn, R., Nicholls, A.J., Arterburn, S. and Dumont, E. (2000). Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin. Transplant. 14, 179-188 DOI ScienceOn |
70 | Pawinski, T., Hale, M., Korecka, M., Fitzsimmons, W. E. and Shaw, L. M. (2002). Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin. Chem. 48, 1497-1504 |
71 | Pillans, P. I., Rigby, R J., Kubler, P., Willis, C., Salm, P., Tett, S. E. and Taylor, P. J. (2001). A retrospective analysis of mycophenolic acid and cyclosporine concentrations with acute rejection in renal transplant recipients. Clin. Biochem. 34, 77-81 DOI ScienceOn |
72 | Lee, W. A., Gu, L., Miksztal, A. R., Chu, N., Leung, K. and Nelson, P. H. (1990). Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm. Res. 7, 161-166 DOI ScienceOn |
73 | Lipsky, J. J. (1996). Mycophenolate mofetil. Lancet 348, 1357-1359 DOI ScienceOn |
74 | Shaw, L. M., Holt, D. W., Oellerich, M., Meiser, B. and van Gelder, T. (2001). Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion. Ther. Drug Monit. 23, 305-315 DOI ScienceOn |
75 | Shaw, L. M., Korecka, M., Aradhye, S., Grossman, R., Bayer, L., Innes, C., Cucciara, A., Barker, C., Naji, A., Nicholls, A. and Brayman, K. (2000). Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin. Pharmacol. 40, 624-633 DOI ScienceOn |
76 | Mourad, M., Malaise, J., and Chaib Eddour, D., De Meyer, M., Konig, J., Schepers, R., Squiffiet, J.P. and Wallemacq, P. (2001) Correlation of mycophenolic acid pharrnacokinetic parameters with side effects in kidney transplant patients treated wioth mycophenolate mofetil. Clin. Chem. 47, 88-94 |
77 | Shaw, L. M., Holt, D. W., Keown, P., Venkataramanan, R. and Yatscoff, R.W. (1999). Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin. Ther. 21, 1632-1652 DOI ScienceOn |
78 | Shaw, L. M. and Nowak, I. (1995). Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther. Drug Monit. 17, 685-689 DOI ScienceOn |
79 | Smak Gregoor, P. J., van Gelder, T, Hesse, C. J., van der Mast, B. J., van Besouw, N.M. and Weimar, W. (1999). Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporine: a crosssectional study. Nephrol. Dial. Transplant. 14, 706-708 DOI ScienceOn |
80 | Nicholls, A. J. (1998). Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin. Chem. 31, 329-333 |
81 | Nowack, R., Gobel, U., Klooker, P., Hergesell, O., Andrassy, K. and van der Woude, F. J. (1999). Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangitis: a pilot study in 11 patients with renal involvement. J Am. Soc. Nephrol. 10, 1965-1971 |
82 | Tricontinental Mycophenolate Mofetil Renal Renal Transpalntation Study Group (1996). A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection incadaveric renal transplantation. Transplantation 61, 1029-1037 DOI ScienceOn |
83 | US Renal Transplant Mycophenolate Mofetil Study Group. (1999). Mycophenolate mofetil in cadaveric renal transplantation. Am. J Kidney Dis. 34,296-303 DOI ScienceOn |
84 | Ransom, J. T (1995). Mechanism of action of mycophenolate mofetil. Ther. Drug. Monit, 17, 681-684 DOI ScienceOn |
85 | van Besouw, N. M., van der Mast, B. J., Smak Gregoor, P. J., Hesse, C. J., IJzermans, J. N., van Gelder, T. and Weimar, W (1999). Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol. Dial. Transplant. 14, 2710-2713 DOI ScienceOn |
86 | van Gelder, T., Klupp, J., Barten, M.J., Christians, U. and Morris, R. E. (2001). Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther. Drug Manit. 23, 119-128 DOI ScienceOn |
87 | Pirsch, J. D. and Sollinger, H. W. (1996). Mycophenolate mofetil-clinical and experimental experience. Ther. Drug Monit. 18, 357-361 DOI ScienceOn |
88 | Schutz, E., Shipkova, M., Armstrong, V. W., Wieland, E. and Oellerich, M. (1999). Identification of pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin. Chem. 45, 419-422 |
89 | Schutz, E., Armstrong, V. W., Shipkova, M., Weber, L., Niedmann, P. D., Lammersdorf, T, Wiesel, M., Mandelbaum, A., Zimmerhackl, L. B., Mehls, O., Tonshoff, B. and Oellerich, M. (1998). Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. Transplant. Proc. 30, 1182-1184 DOI ScienceOn |
90 | Wieland, E., Shipkova, M., Schellhaas, U., Schutz, E., Niedmann, P. D., Armstrong, V.W. and Oellerich, M. (2000). Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects. Clin. Biochem. 33, 107-113 DOI ScienceOn |
91 | Wollenberg, K., Krumme, B., Pisarski, P., Schollmeyer, P. and Kirste, G. (1998). Pharmacokinetics of mycophenolic acid in the early period after kidney transplantation. Transplant. Proc. 30, 4090-4091 DOI ScienceOn |